Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Many studies report the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to better estimate the level and distribution of SARS-CoV-2 infection, identify high-risk groups, and inform public health decision making. Methods: In this systematic review and meta-analysis, we searched publication databases, preprint servers, and grey literature sources for seroepidemiological study reports, from January 1, 2020 to December 31, 2020. We included studies that reported a sample size, study date, location, and seroprevalence estimate. We corrected estimates for imperfect test accuracy with Bayesian measurement error models, conducted meta-analysis to identify demographic differences in the prevalence of SARS-CoV-2 antibodies, and meta-regression to identify study-level factors associated with seroprevalence. We compared region-specific seroprevalence data to confirmed cumulative incidence. PROSPERO: CRD42020183634. Results: We identified 968 seroprevalence studies including 9.3 million participants in 74 countries. There were 472 studies (49%) at low or moderate risk of bias. Seroprevalence was low in the general population (median 4.5%, IQR 2.4–8.4%); however, it varied widely in specific populations from low (0.6% perinatal) to high (59% persons in assisted living and long-term care facilities). Median seroprevalence also varied by Global Burden of Disease region, from 0.6% in Southeast Asia, East Asia and Oceania to 19.5% in Sub-Saharan Africa (p<0.001). National studies had lower seroprevalence estimates than regional and local studies (p<0.001). Compared to Caucasian persons, Black persons (prevalence ratio [RR] 3.37, 95% CI 2.64–4.29), Asian persons (RR 2.47, 95% CI 1.96–3.11), Indigenous persons (RR 5.47, 95% CI 1.01–32.6), and multi-racial persons (RR 1.89, 95% CI 1.60–2.24) were more likely to be seropositive. Seroprevalence was higher among people ages 18–64 compared to 65 and over (RR 1.27, 95% CI 1.11–1.45). Health care workers in contact with infected persons had a 2.10 times (95% CI 1.28–3.44) higher risk compared to health care workers without known contact. There was no difference in seroprevalence between sex groups. Seroprevalence estimates from national studies were a median 18.1 times (IQR 5.9–38.7) higher than the corresponding SARS-CoV-2 cumulative incidence, but there was large variation between Global Burden of Disease regions from 6.7 in South Asia to 602.5 in Sub-Saharan Africa. Notable methodological limitations of serosurveys included absent reporting of test information, no statistical correction for demographics or test sensitivity and specificity, use of non-probability sampling and use of non-representative sample frames. Discussion: Most of the population remains susceptible to SARS-CoV-2 infection. Public health measures must be improved to protect disproportionately affected groups, including racial and ethnic minorities, until vaccine-derived herd immunity is achieved. Improvements in serosurvey design and reporting are needed for ongoing monitoring of infection prevalence and the pandemic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, given the known variability in dual human data extraction accuracy (reported rates: 65.8-85.5%) 14-19 , original author-extracted values were not treated as a definitive gold standard”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior research has shown wide variability in the accuracy of dual human extraction, with reported rates ranging from 65.8-85.5% 14-19 .”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For human data extraction, we determined sample size using a McNemar test for sample size approximation. Using an estimated human accuracy of 80% (reported rates: 65.8-85.5%) 14-19 , LLM accuracy of 90%, and 95% confidence, we determined a minimum number of 204 variables per study to be extracted.”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827 · cited 1×
“All meta-analysis and meta-regression were done using the meta package in R [34].”
MethodCochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundMunn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131 · cited 1×
“A modified Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Prevalence Studies was used to assess study risk of bias [17].”
MethodBi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S. A., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,958 · cited 1×
“Our review found that health care workers who had close contact with confirmed COVID19 cases had a higher risk of seropositivity, consistent with previous reports [45].”
ResultRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., Salanti, G., & Low, N. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003346 · Cited by 1,000 · cited 1×
“However, these case counts inevitably underestimate the true cumulative incidence of infection [3] because of limited diagnostic test availability [4], barriers to testing accessibility [5], and asymptomatic infections [6].”
Background
Research works printed but not linked: 2
- American Society for Microbiology. Supply Shortages Impacting COVID-19 and Non-COVID Testing [Internet]. 2020 [cited 2021 May 15]. Available from: https://asm.org/Articles/2020/September/Clinical- Microbiology-Supply-Shortage-Collecti-1
- Wolters Kluwer. COVID-19 Tools and Resources for Clinicians: Expert Searches [Internet]. 2020. Avail- able from: https://tools.ovid.com/coronavirus/?utm_source=marketo&utm_medium=email&utm_ campaign=0-v035&utm_term=all%20ovid&mkt_tok=eyJpIjoiWkRRM01qWXlPRFV5TnpKbCIsInQiO iIydVZWOUYyRFJJYlg1ZUR4T29sY0tCMGpWcHBVbnpTQWpLTGZQb0RjbnlidUQ2U3lVekxC WjNrN0U4SkZLOE9sM0lHTUlmdXEzMXJcL0pWQkhhSzdGYU92cXJ1RXZ4T3BMc2tmT1ZFMm h2Z09cL0d1MEh6RnowK2NJMGRUbEZSdGQ0VmpQUmpybkljWEpPVnFDUTdnZnlRUT09In0%3D
Cited by
Items 101–200 of 238
How enlightened self-interest guided global vaccine sharing benefits all: A modeling study
Han, Z., Chen, L., Hao, Q., He, Q., Budeski, K., Jin, D., Xu, F., Tang, K., & Li, Y. (2023) · Journal of Global Health · doi:10.7189/jogh.13.06038 · Cited by 7
“To minimise these errors, we refer to the most comprehensive systematic review of COVID-19 seroprevalence, which contains 968 studies with more than 9.3 million participants in 74 countries [48].”
MethodInfluentialHerlinda, O., Bella, A., Kusnadi, G., Nurshadrina, D. S., Akbar, M. T., Nida, S., Salama, N., Ariawan, I., & Saminarsih, D. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261931 · Cited by 7
Racey, C. S., Booth, A., Albert, A., Smith, L., Krajden, M., Murray, M. C. M., Côté, H. C. F., Gottschlich, A., Goldfarb, D. A., Sadarangani, M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062567 · Cited by 7
Limitations introduced by a low participation rate of SARS-CoV-2 seroprevalence data
Pluss, O., Campbell, H., Pezzı, L., Morales, I., Roell, Y., Quandelacy, T. M., Arora, R. K., Boucher, E. L., Lamb, M. M., Chu, M., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac178 · Cited by 8
“The SeroTracker study database compiles a wide range of seroprevalence data, including: published and unpublished academic studies in databases (PubMed, medRxiv, bioRxiv, World Health Organization International Clinical Trials Registry Platform) and high-impact medical journals [the British Medical Journal (BMJ), the…”
BackgroundMethodInfluentialSelf-citationMatias, W. R., Fulcher, I., Sauer, S. M., Nolan, C. P., Guillaume, Y., Zhu, J., Molano, F. J., Uceta, E., Collins, S., Slater, D., et al. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01502-4 · Cited by 7
“Our main SARS-CoV-2 seroprevalence estimate was the proportion of the population that had IgG antibodies detected as this aligns with prior studies [23].”
ResultYoon, K., Kim, J., Peck, K. R., Kim, H. S., Lee, H., Hwang, Y.-S., Lee, S. Y., Cho, S., Lee, H. J., Kim, Y., et al. (2022) · Epidemiology and Health · doi:10.4178/epih.e2022085 · Cited by 6
“First, convenience sampling using residual blood collected from medical facilities, as was done in this study, was not conclusive in terms of regional representation and generalizability, although a recent meta-analysis showed that many studies are still being conducted in hospital settings worldwide due to practical…”
Mohan, Y., Charumathi, B., Eashwar, V. M. A., Jain, T., & Abiramasundari, V. K. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_687_20 · Cited by 6
“These findings may have been since risk perception is less among males and younger age groups, which in turn affect their attitude on the responsible use of PPE and social distancing measures.[16,17] Angiotensin converting enzyme inhibitor (ACE‐2), which is major receptor for COVID‐19, was found to be more expressed i…”
ResultSeroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave
Sočan, M., Prosenc, K., & Mrzel, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043665 · Cited by 6
Sulcebe, G., Ylli, A., Kurti-Prifti, M., Ylli, Z., Shyti, E., Dashi-Pasholli, J., & Cenko, F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19547 · Cited by 6
Temporal trends in disparities in COVID-19 seropositivity among Canadian blood donors
Yu, Y., Knight, M. J., Gibson, D., O’Brien, S. F., Buckeridge, D. L., & Russell, W. A. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae078 · Cited by 6
“27,36 Despite these selection biases, our findings for the earlier pandemic period are consistent with findings from other cohorts.”
ResultSawitri, A. A. S., Yuliyatni, P. C. D., Astuti, P. A. S., Ajis, E., Prasetyowati, E. B., Husni, Morgan, J., Mika, J., Praptiningsih, C. Y., Mangiri, A., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000727 · Cited by 6
“This condition occurred not only in Indonesia but elsewhere, as one systematic review has reported that numbers of infections estimated by serosurveys are always higher than actual number of cases detected [27].”
BackgroundManna, O. K., Clemens, S. A. C., & Clemens, R. L. (2023) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003916 · Cited by 8
Hoebel, J., Busch, M. A., Grabka, M. M., Zinn, S., Allen, J., Gößwald, A., Wernitz, J., Goebel, J., Steinhauer, H. W., Siegers, R., et al. (2021) · Social Science Open Access Repository (GESIS – Leibniz Institute for the Social Sciences) · doi:10.25646/7852 · Cited by 6
Seroepidemiological study on the spread of SARS-CoV-2 in Germany:
Hoebel, J., Busch, M. A., Grabka, M. M., Zinn, S., Allen, J., Gößwald, A., Wernitz, J., Goebel, J., Steinhauer, H. W., Siegers, R., et al. (2021) · PubMed · doi:10.25646/7853 · Cited by 11
Sergeeva, M. V., Vasilev, K., Romanovskaya-Romanko, E., Yolshin, N. D., Pulkina, A., Shamakova, D., Shurygina, A.-P. S., Muzhikyan, A., Lioznov, D. A., & Stukova, M. (2024) · Vaccines · doi:10.3390/vaccines13010015 · Cited by 5
Malijan, G. M., Edwards, T., Agrupis, K. A., Suzuki, S., Villanueva, A. M. G., Sayo, A. R., Guzman, F. D., Dimapilis, A. Q., Solante, R., Telan, E. O., et al. (2022) · Tropical Medicine and Health · doi:10.1186/s41182-022-00468-7 · Cited by 5
Jalloh, M. F., Tinuga, F., Dahoma, M., Rwebembera, A. A., Kapologwe, N., Magesa, D., Mukurasi, K., Rwabiyago, O. E., Kazitanga, J. C., Miller, A., et al. (2024) · Global Health Science and Practice · doi:10.9745/ghsp-d-23-00281 · Cited by 5
Goh, F. T., Chew, Y. Z., Tam, C. C., Yung, C. F., & Clapham, H. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100581 · Cited by 5
SARS-CoV-2 infections in infants in Haiti 2020–2021; evidence from a seroepidemiological cohort
Louis, R., Pu, R., Logan, T. D., Trimmer-Smith, L., Chamblain, R., Gallagher, A., Rochars, V. M. B. D., Nelson, E. J., Cummings, D. A. T., Long, M. T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273482 · Cited by 6
“While there have been a number of population-based serologic studies that have assessed rates of SARS-CoV-2 infection in the developed world, available seroprevalence data are more limited in the developing world [1–4].”
SARS-CoV-2 seroprevalence in workers from a Colombian University Hospital
Moreno, K., Sáenz, L., Villar, J. C., Herrera, E. V., Franco, J. E. P., Varón-Vega, F. A., Cortés, R. G., Gualdrón, A. S., & Becerra, M. S. S. (2023) · Occupational Medicine · doi:10.1093/occmed/kqad003 · Cited by 5
Amati, R., Piumatti, G., Franscella, G., Buttaroni, P., Camerini, A.-L., Corna, L., Levati, S., Fadda, M., Fiordelli, M., Annoni, A. M., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043703 · Cited by 6
Richter, E., Liebl, D., Schulte, B., Lehmann, N., Fuhrmann, C., Jöckel, K., Ioannidis, J. P. A., & Streeck, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-32441-7 · Cited by 6
Sakala, M., Johnson, C., Chirombo, J., Sacks, J. A., Baggaley, R. C., & Divala, T. H. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002369 · Cited by 7
Prevalence of SARS‐CoV‐2 Antibodies in Kosovo‐Wide Population‐Based Seroepidemiological Study
Ramadani, N., Hoxha‐Gashi, S., Gexha‐Bunjaku, D., Kalaveshi, A., Jakupi, X., Humolli, I., Vaughan, A., Pebody, R. G., Kaçaniku‐Gunga, P., & Jashari, V. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70004 · Cited by 5
Ukwishaka, J., Mela, C. F., Aseneh, J. B., Ettaj, M., Ilboudo, D., Danwang, C., Samadoulougou, S., & Kirakoya‐Samadoulougou, F. (2024) · BMC Public Health · doi:10.1186/s12889-024-20364-5 · Cited by 5
“Data were transformed using a Double Arcsine Trans-formation as described by Freeman-Tukey [32].”
MethodSARS-CoV-2-Seroprävalenz bei Kindern und Jugendlichen in Deutschland – ein Überblick
Thamm, M., Buttmann‐Schweiger, N., Fiebig, J., Poethko‐Müller, C., Prütz, F., Sarganas, G., & Neuhauser, H. K. (2021) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-021-03448-0 · Cited by 9
Hansen, C. B., Dvoncova, K., Pérez‐Alós, L., Fogh, K., Madsen, J. R., Garred, C. H., Jarlhelt, I., Nielsen, P. B., Petersen, S. S., Fjordager, C. G., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13637 · Cited by 6
Estimating Enteric Fever Seroincidence in Bangladesh Using Rapid Serosurveys
Munira, S. J., Kanon, N., Islam, N., Kabir, M. S., Sarkar, A., Polash, S. A., Rahman, H., Carter, A., Charles, R. B., Andrews, J. R., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag197 · Cited by 4
“This approach has been successfully used for infectious diseases such as COVID-19, dengue, and hepatitis E [8–11].”
Staetsky, L. (2023) · Journal of Biosocial Science · doi:10.1017/s0021932023000068 · Cited by 4
Soubgui, A. F. M., Mboussi, W. S. N., Foko, L. P. K., Enyegue, E. L. E., & Mogtomo, M. L. K. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002380 · Cited by 4
Bratcher, A. M., Kao, S. Z., Chun, K., Petropoulos, C. J., Gundlapalli, A. V., Jones, J. M., & Clarke, K. E. N. (2024) · Emerging infectious diseases · doi:10.3201/eid3011.240043 · Cited by 5
Awartani, F., Qutob, N., & Asia, M. (2022) · Vaccines · doi:10.3390/vaccines10081332 · Cited by 4
“Consequently, the accuracy of such seroprevalence studies has been doubted due to insufficient specificity of the serologic assay for a low prevalence population and due to potential sampling bias [10].”
BackgroundHeiskanen, A., Galipeau, Y., Langlois, M., Little, J., & Cooper, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811629 · Cited by 4
“Comparable to results found in more extensive systematic reviews [7,39], most studies found no association between sex and seropositivity for SARS-CoV-2 antibodies.”
ResultKrogsgaard, L. W., Espenhain, L., Tribler, S., Jørgensen, C. S., Hansen, C. H., Møller, F. T., Helmuth, I. G., Sönksen, U. W., Vangsted, A., Ullum, H., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s383491 · Cited by 5
Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort
Ojji, D. B., Sancilio, A., Shedul, G. L., Orji, I. A., Chopra, A., Abu, J., Akor, B., Ripiye, N., Akinlade, O., Okoye, D., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000549 · Cited by 5
“4%) of the general population (through December 2020) [17].”
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 6
Hou, C., Williams, S., Soto, G. S. T., Boyle, V., Rainford, D., Vicino, S., Magee, M., Chung, Y., LaBaer, J., & Murugan, V. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003893 · Cited by 4
Santigli, E., Lindner, M., Kessler, H. H., Jakse, N., & Fakheran, O. (2025) · Scientific Reports · doi:10.1038/s41598-025-91529-4 · Cited by 4
Pagheh, A. S., Asghari, A., Romenjan, K. A., Mousavi, T., Abedi, F., Ziaee, A., Malakimoghadam, H., & Ziaee, M. (2022) · Iranian Journal of Microbiology · doi:10.18502/ijm.v14i2.9178 · Cited by 4
Cenko, F., Ylli, A., Kurti-Prifti, M., Shyti, E., Lazri, E., Perry, M. J., & Sulcebe, G. (2022) · Journal of Global Health · doi:10.7189/jogh.12.03054 · Cited by 4
Population-based sero-epidemiological investigation of SARS-CoV-2 infection in Somalia
Hossain, M. S., Derow, M., Mohamed, S. I., Abukar, H. M., Qayad, M. G., Malik, S. M. M. R., Mengistu, K. F., Obsie, A. A. A., & Anwar, I. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.04.016 · Cited by 5
“1 times higher than the corresponding cumulative incidence of COVID-19 infections [10].”
Ahmad, R. A., Indriani, C., Arisanti, R. R., Nanda, R. O., Mahendradhata, Y., & Wibawa, T. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000698 · Cited by 4
Chisale, M., Sinyiza, F. W., Kaseka, P. U., Chimbatata, C. S., Mbakaya, B. C., Wu, T.-S. J., Nyambalo, B. W., Chauma-Mwale, A., Chilima, B., Yu, K.-L. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11071185 · Cited by 4
Population-level differences in COVID-19 prevalence, severity, and clinical outcome
Dasgupta, I., Saini, S., Khan, M. A., & Chaudhary, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18769-8.00008-8 · Cited by 6
Ioannidis, J. P. A. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-024-01169-7 · Cited by 3
Seroprevalence of SARS-CoV-2 among Blood Donors in the Republic of Congo
Mokono, S. O., Nanitelamio, E. P. C. L., Mbani, C. J., Tabapika, A., Taty, T., Ontsira, N. E. N., & Moukassa, D. (2022) · Open Journal of Blood Diseases · doi:10.4236/ojbd.2022.124013 · Cited by 3
Alquero, J. N. M., Estanislao, P. M. S., Hermino, S. M. M., Manding, R. D. M., Robles, J. E. D., Canillo, C. M. A., & Tantengco, O. A. G. (2024) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2024.100700 · Cited by 3
Soroprevalência de anticorpos do vírus SARS-CoV-2 em escolares no município de São Paulo, 2020
Kamioka, G. A., Madalosso, G., de Albuquerque, J. O. M., Costa, S. A., Ferreira, P. B., Sato, A. P. S., Glasser, P. R., Pino, F. A., Burihan, P. C. P. R., de Carvalho, A. C. A., et al. (2023) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2023057004782 · Cited by 3
“The highest seroprevalence in the black or brown people and in the most vulnerable social class was similar to that found in several studies 20 .”
ResultSeroprevalence of SARS-CoV-2 IgG among healthcare workers in Lagos, Nigeria
Ige, F. A., Ohihoin, A. G., Osuolale, K. A., Dada, A., Onyia, N., Johnson, A., Okwuraiwe, A. P., Odediran, O. O., Liboro, G., Aniedobe, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292440 · Cited by 3
“Estimates of seroprevalence in HCWs have been reported in countries around the world and seroprevalence levels differ by region and stage of the pandemic [12, 13].”
BackgroundMunywoki, P. K., Bigogo, G., Nasimiyu, C., Ouma, A., Aol, G., Oduor, C., Rono, S., Auko, J., Agogo, G. O., Njoroge, R., et al. (2023) · Gates Open Research · doi:10.12688/gatesopenres.14684.1 · Cited by 3
Touil, N., Touzani, C. D., Benaissa, E., Kasouati, J., Rhazzar, Z., Annaz, H. E., Mrimar, N. E., Neffah, L., Abi, R., Tagajdid, R., et al. (2023) · African Health Sciences · doi:10.4314/ahs.v23i3.46 · Cited by 3
Misra, P., Garg, P. K., Awasthi, A., Kant, S., Rai, S. K., Ahmad, M., Guleria, R., Deori, T. J., Mandal, S., Jaiswal, A., et al. (2023) · Cureus · doi:10.7759/cureus.48824 · Cited by 3
“Additionally, as the world moves through to an era of vaccine and virus variant, synthesizing sero-epidemiological findings are increasingly vital in tracking the spread of infection, identifying the disproportionately affected groups, and measuring the progress towards herd immunity [1].”
BackgroundSeroprevalence of SARS‐CoV‐2 in 10 Regional Capitals of Cameroon, October–December 2020
Sachathep, K. K., Duong, Y. T., Reid, G. A., Dokubo, E. K., Shang, J. D., Ndongmo, C. B., Gabriel, E., Tharp, G., Dimite, L. E., N'Dir, A., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13267 · Cited by 3
Die COVID-19-Pandemie in Steglitz-Zehlendorf – sozialräumliche Betrachtung des Infektionsgeschehens
Bettge, S., George, M., Michaelis, A., & Nowka, A. (2022) · Publication server of the Robert Koch Institute (Robert Kock Institute) · doi:10.25646/9495 · Cited by 3
Koureas, M., Bogogiannidou, Z., Vontas, A., Kyritsi, M. A., Mouchtouri, V. Α., Dadouli, K., Anagnostopoulos, L., Mina, P., Matziri, A., Ντούσκα, Μ., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020295 · Cited by 4
“A recently published meta-analysis by Bobrovitz et al. (2021) estimated the ratio between seroprevalence estimates and the corresponding cumulative incidence of SARS-CoV-2 infection nine days prior at 18.1 (IQR 5.9–38.7) by synthesizing data from 49 national-wide studies [25].”
MethodInfluentialRees, E. M., Waterlow, N. R., Lowe, R., & Kucharski, A. J. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16701.3 · Cited by 8
Systematic literature review of SARS-CoV-2 seroprevalence surveys in Canada through April 2021
Major, M., Majowicz, S. E., Oremus, M., Jiménez, L., Angulo, F. J., & Horton, S. (2022) · IJID Regions · doi:10.1016/j.ijregi.2022.07.010 · Cited by 3
“…ratio calculated within the global review was 18.1x higher than the reported incidence of COVID-19, which was higher than that observed in Canada, but demonstrates a similar issue with relying upon reported infections to monitor population exposure to SARS-CoV-2 ( Bobrovitz et al., 2021 ).”
InfluentialWilleit, P., Kimpel, J., Winner, H., Harthaller, T., Schäfer, H., Bante, D., Falkensammer, B., Rössler, A., Riepler, L., Ower, C., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.989337 · Cited by 3
Ahmed, A., DeWitt, M., Dantuluri, K. L., Castri, P., Buahin, A., Lagarde, W. H., Weintraub, W., Rossman, W., Santos, R. P., Gibbs, M. A., et al. (2023) · Epidemiology and Infection · doi:10.1017/s0950268823000481 · Cited by 3
“While national studies tend to report lower seroprevalence estimates than local studies [24], this variation may be also explained by important differences in study design.”
BackgroundEvaluating the number of unvaccinated people needed to exclude to prevent SARS-CoV-2 transmissionsPreprint
Prosser, A., Helfer, B., & Streiner, D. L. (2021) · medRxiv · doi:10.1101/2021.12.08.21267162 · Cited by 3
“This is shown by the extreme variation in underreporting estimates.”
InfluentialCOVID-19 serological survey utilizing antenatal serum samples in British Columbia
Márquez, A. C., Beitari, S., Valadbeigy, T., Sbihi, H., Zlosnik, J. E. A., Forward, L., Mansour, S., Nesbitt, Z., Tanunliong, G., Krajden, M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127310 · Cited by 2
Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
Krashias, G., Deeba, E., Constantinou, A., Hadjiagapiou, M. S., Koptides, D., Richter, J., Tryfonos, C., Bashiardes, S., Lambrianides, A., Loizidou, M. A., et al. (2021) · Microorganisms · doi:10.3390/microorganisms10010085 · Cited by 2
“83% [24], considerably lower than the seroprevalence detected in our NegV group.”
BackgroundIncidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal
Costa, J. P., Meireles, P., Rodrigues, P., & Barros, H. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2035429 · Cited by 2
Rubilar, P. A., Hirmas, M., Matute, I., Browne, J., Little, C., Ruz, G. A., Aguilera, X., Ávila, C., Vial, P., & Mackenzie, T. G. (2022) · Medwave · doi:10.5867/medwave.2022.03.002553 · Cited by 2
Araújo, A. A. D. S., Quintans‐Júnior, L. J., Heimfarth, L., Schimieguel, D. M., Corrêa, C. B., de Moura, T. R., Cavalcante, R. C. M., Grespan, R., Quintans, J. D. S. S., dos Santos, D. M., et al. (2022) · Pathogens and Global Health · doi:10.1080/20477724.2022.2121366 · Cited by 2
Kaboré, N. F., Ouédraogo, S., Kamga, A. M., TRAORE, I. T., Kania, D., Badolo, H., Sanou, G. S., Koné, A., Yara, M., Kagone, T., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08361-2 · Cited by 2
“Early studies based on serological testing indicated a similar level of infection across continents [9].”
BackgroundUniversität in der Pandemie / L'Université en temps de pandémie
Kazmaier, D., & Weber, F. (2023) · transcript Verlag eBooks · doi:10.14361/9783839467893 · Cited by 2
Ouédraogo, S., Traoré, I., Kania, D., Kaboré, N. F., Kamga, A. M., Badolo, H., Yara, M., Sanou, G. S., Koné, A., Kagone, T., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13216 · Cited by 2
“12,13 High-quality, large-scale sero-prevalence studies are needed to more accurately estimate the true burden of COVID-19 and to understand the dynamics and nature of immune responses to SARS-CoV-2 infection in the African epidemiological context.”
BackgroundSana, A., Djemaï, É., Vreyer, P. D., Thivillon, T., Badolo, H., Berthé, A., & Kania, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305850 · Cited by 2
Prosperi, C., Hasan, A. Z., Winter, A. K., Chaaithanya, I. K., Salvi, N., Sharma, S., Bansal, A. K., Chauhan, S., Kulkarni, R. N., Lachyan, A. S., et al. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001353 · Cited by 2
Knežević, D., Petković, M. R., Božić, L., Miljuš, N., Mijović, B., Aćimović, J., Dević, J. Đ., Puhalo-Sladoje, D., Mašić, S., Spaić, D., et al. (2022) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2022.01706 · Cited by 3
“As the world is moving through the era of vaccination, studies of SARS-CoV-2 seroprevalence are very important for tracking infection spreading, identifying the disproportionally affected groups and measuring the progress of collective immunity [13].”
BackgroundHigh seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia
Almudarra, S., Kamel, S., Abd‐Ellatif, E. E., Alaswad, R., Alruwaily, A., Almowald, S., Alqunaibet, A., Almudiaheem, A., Almutlaq, H., Alserehi, H., et al. (2021) · Infection · doi:10.1007/s15010-021-01726-2 · Cited by 3
Serorreactividad al SARS-CoV-2 en trabajadores de un campus universitario en Bogotá, Colombia
González, J. M., Santos‐Barbosa, J. C., Jaller, C., Romero, G., Hernandéz, L. J., Guevara‐Suarez, M., & Restrepo, S. (2022) · Revista de la Academia Colombiana de Ciencias Exactas Físicas y Naturales · doi:10.18257/raccefyn.1590 · Cited by 2
Abhold, J., Wozniak, A. K., Mulcahy, J., Walsh, S., Zepeda, E., Demmer, R. T., Yendell, S. J., Hedberg, C. W., Ulrich, A. K., Wurtz, R. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279660 · Cited by 2
Lemyre, F. C., Honfo, S. H., Caya, C., Cheng, M. P., Colwill, K., Corsini, R., Gingras, A., Jassem, A. N., Krajden, M., Márquez, A. C., et al. (2023) · Vox Sanguinis · doi:10.1111/vox.13545 · Cited by 2
“These assays proved essential to further knowledge of the immune response to SARS-CoV-2 and to study population-level immunity through serosurveys [7].”
MethodSelf-citationBijira, B. B., Muderhwa, J. B., Nabintu, A. B., Birato, Y. C., Delphin, M. K., & Katchunga, P. B. (2023) · Epidemiology and Health System Journal · doi:10.34172/ehsj.2023.22 · Cited by 1
“Epidemiological studies in the general population show relatively lower SARS-CoV-2 seroprevalences 11-13 than hospital studies.”
BackgroundSeabra, S. G., Merca, F., Pereira, B., Fonseca, I., de Carvalho, A. C. C., Brito, V., Alves, D. A., Libin, P., Martins, M. D. R. O., Miranda, M., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1326125 · Cited by 2
“One of the public health strategies carried out early in the pandemic was the conduction of serological surveys to estimate SARS-CoV-2 seroprevalence in the general community or in target populations (3–6).”
BackgroundInfluentialCheng, B., Loeschnik, E., Selemon, A., Hosseini, R., Yuan, J., Ware, H., Ma, X., Cao, C., Bergeri, I., Subissi, L., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13283 · Cited by 1
“Further details on extraction methods can be found in a previous publication [22].”
BackgroundSelf-citationNonrepresentativeness in Population Health Research: Evidence from a COVID-19 Antibody Study
Dutz, D., Greenstone, M., Hortaçsu, A., Lacouture, S., Mogstad, M., Shaikh, A. M., Torgovitsky, A., & van Dijk, W. (2024) · American Economic Review Insights · doi:10.1257/aeri.20230195 · Cited by 2
“E Comparable COVID-19 serological surveys Bobrovitz et al. (2021) perform a systematic review of serological studies with the goal of identifying and subsequently synthesizing studies that tested for COVID-19 antibodies.”
BackgroundMethodInfluentialPredictors of seropositivity to SARS-CoV-2 among employees at a large urban medical center
Kupferwasser, D., Flores, E. A., Merino, P., Tran, D. P., Liu, H., Huang, Y., Bolaris, M., Nguyen, M. H., Gonzales, M. C., Silva, W. D., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20274-6 · Cited by 1
Prosperi, C., Hasan, A. Z., Winter, A. K., Chaaithanya, I. K., Salvi, N., Chauhan, S., Kulkarni, R. N., Lachyan, A. S., Gawali, P., Kapoor, M., et al. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001389 · Cited by 1
Significant Driving Factors in the Evolution of the COVID-19 Epidemic
Sun, J., Chen, X., & Zhang, L. (2024) · Sustainability · doi:10.3390/su17010110 · Cited by 1
Lorenz, E., Amuasi, J., Randrianarisoa, T., Rasamoelina, T., Gunga, L., Benke, D., Ströbele, J., Kettenbeil, J., Loag, W., Andriamahandry, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334627 · Cited by 1
“A systematic review by Bobrovitz et al. [8] found that only 22% of SARS-CoV-2 seroprevalence studies worldwide used population-based probability sampling approaches, while the majority relied on selective convenience samples from blood donors, healthcare workers, or outpatients.”
Phommasone, K., Souksakhone, C., Chanthongthip, A., Phonemixay, O., Keokhamphoui, C., Priet, S., Barthélémy, K., de Lamballerie, X. N., Vongsouvath, M., Ashley, E. A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336239 · Cited by 1
Braeye, T., Abrams, S., & Hens, N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0328144 · Cited by 1
Africa’s COVID-19 Experience—A Window of Opportunity to Act
Ofotokun, I., & Sheth, A. N. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24556 · Cited by 1
COVID-19 in Type 1 Diabetes Mellitus adult patients; effect of infection and vaccination
Albatayneh, E. M., Alabdallat, Y. J., Ayash, H., Abduh, M. S., & Mahgoub, S. S. (2022) · Medical Science · doi:10.54905/disssi/v26i122/ms155e2244 · Cited by 1
Evaluation Protocol for SARS-CoV-2 Serological Assays
Gededzha, M. P., Jugwanth, S., Mampeule, N., Zwane, N., David, A., Scott, L. E., Stevens, W. S., & Mayne, E. S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2395-4_23 · Cited by 1
Karunathilake, R. P., Hewage, S., Vidanapathirana, G. U., Kumara, A., Ranasinghe, P., Noordeen, F., Gawarammana, I., & Ratnatunga, C. N. (2022) · BMC Public Health · doi:10.1186/s12889-022-14381-5 · Cited by 1
“Investigations into serological evidence of infection in RT-PCR negative asymptomatic individuals is sparse [11].”
BackgroundProsser, A., Helfer, B., & Streiner, D. L. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13813 · Cited by 1
Bakr, S., Ezzat, E. M., Salem, K. M., Masoud, M., & Abdelaziz, H. E. M. (2023) · Pan African Medical Journal · doi:10.11604/pamj.2023.45.22.36513 · Cited by 1
“Population-wide studies on SARS-CoV-2 seroprevalence in numerous systemic reviews and meta-analyses indicated worldwide variations in the seroconversion reflecting the dissimilarities in community transmission that might be based on geographic latitudes and/or climate, local resources, public health behavioral respons…”
BackgroundAnalysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020–2021
Greene, M. K., Smyth, P., English, A. R., McLaughlin, J. B., Bucholc, M., BAILIE, J. R., McCarroll, J., McDonnell, M., Watt, A. P., Barnes, G., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24184 · Cited by 2
“…Northern Ireland, there are abundant reports of SARS-CoV-2 seroprevalence studies, totalling 4446 in 148 countries and territories as listed on the SeroTracker database [24] as of December 8th , 2023 that have formed the basis of many comprehensive systematic reviews and meta-analyses [25,26].”
BackgroundUptake of SARS-CoV-2 workplace testing programs, March 2020 to March 2021Preprint
Duarte, N., D’Mello, S., Duarte, N., Rocco, S., Wyk, J. V., Pillai, A., Liu, M., Williamson, T. S., & Arora, R. K. (2021) · medRxiv · doi:10.1101/2021.06.29.21259730 · Cited by 1
Self-citationSARS-CoV-2 seroprevalence, vaccination, and hesitancy in agricultural workers in GuatemalaPreprint
Calvimontes, D. M., Krisher, L. K., Cruz-Aguilar, A., Pilloni, D., Crisostomo-Cal, L. E., Castañeda-Sosa, E. A., Butler-Dawson, J., Olson, D., Newman, L. S., & Asturias, E. J. (2022) · medRxiv · doi:10.1101/2022.02.22.22270907 · Cited by 1
“Authors’ affiliations: (1)Fundación para la Salud Integral de los Guatemaltecos – CU, Guatemala; (2) Center for Global Health, Colorado School of Public Health, Aurora, CO, USA; (3) Center for Health, Work & Environment, Colorado School of Public Health, Aurora, CO, USA; (4) Fundación Pantaleon, Guatemala; (5) Hospita…”
BackgroundLei, J., & Soe, P. (2024) · medRxiv · doi:10.1101/2024.03.08.24303942 · Cited by 1
SARS-CoV-2 seroprevalence in Nova Scotia blood donors
O’Brien, S. F., Deeks, S. L., Hatchette, T. F., Pambrun, C., & Drews, S. J. (2024) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2023-0017 · Cited by 1
Geographic Altitude and COVID-19: Parameters for a better recognition of severe disease
Pecho‐Silva, S., Navarro‐Solsol, A. C., Panduro‐Correa, V., Bonilla-Aldana, K., & Rodriguez-Morales, A. J. (2021) · Microbes Infection and Chemotherapy · doi:10.54034/mic.e1172
“5 million cases were reported worldwide (2).”
Grewal, V. S., Bandyopadhyay, K., Jain, A., Dhawan, R., Singh, A., Raikar, K., Dahiya, N., Kharche, C., Srivastava, S., Dutt, M., et al. (2021) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_70_21
Seropositivity Against SARS-Cov-2 Infection in India: A Systematic Review and Meta Analysis
Patrikar, S., Sahu, R., Basannar, D. R., Adhya, S., & Kaushik, S. K. (2022) · Asia Pacific Journal of Public Health · doi:10.1177/10105395221115147
Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan.
Khan, M. N., Khan, H., Shahzad, M. A., bin Ibrahim, M., Arif, M., Kibria, Z., Waheed, U., Saba, N., Shah, I., Sumera, et al. (2022) · PubMed Central · Cited by 1
Metadata
- Authors
- Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., Rahim, H., Ilincic, N., Segal, M., Duarte, N., Van Wyk, J., Yan, T., Atmaja, A., Rocco, S., Joseph, A., Penny, L., Clifton, D. A., Williamson, T., Yansouni, C. P., Evans, T. G., Chevrier, J., Papenburg, J., & Cheng, M. P.
- Affiliations
- University of Calgary (CA)
- University of Oxford (GB)
- McGill University (CA)
- University of Toronto (CA)
- University of Waterloo (CA)
- McGill University Health Centre (CA)
- Corresponding author
- Bobrovitz, Niklas
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-23
- Volume
- 16
- Issue
- 6
- Pages
- e0252617
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8221784
- OpenAlex
- W3173470851
- Cited by
- 246
- References
- 49
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 33 · 2023: 66 · 2022: 81 · 2021: 43
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Federal Open Science Repository of Canada / Le Dépôt fédéral de science ouverte du Canada (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Public Health Agency of Canada via the COVID-19 Immunity Task Force
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulins, seroepidemiology, racial and ethnic disparities, indigenous peoples, long-term care facilities, perinatal infection, cumulative incidence, public health decision-making, infection risk factors, high-risk groups, SARS-CoV-2 variants
- MeSH terms
- COVID-19, COVID-19 Serological Testing, Adolescent, Adult, Aged, Antibodies, Viral, Child, Health Personnel, Humans, Middle Aged, Sensitivity and Specificity, Incidence, Seroepidemiologic Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.